Impact of Maximal Strength Training on COPD Patients
Study on Impact of Maximal Strength Training in Patients With COPD: Physiological and Clinical Implications
This study is testing whether combining strength training with endurance training can help people with COPD improve their exercise ability and muscle function.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 50 Years to 80 Years |
| Sex | All |
| Sponsor | Istituti Clinici Scientifici Maugeri SpA Academic / other |
| Locations | 1 site (Lumezzane, Brescia) |
| Trial ID | NCT03799354 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of Maximal Strength Training (MST) combined with Endurance Training (ET) on patients with Chronic Obstructive Pulmonary Disease (COPD). It aims to assess improvements in exercise tolerance and muscle function, particularly focusing on the Rate of Force Development (RFD) and aerobic endurance. The study includes patients who meet specific COPD criteria and excludes those with other significant health issues. The methodology involves structured training sessions designed to enhance physical capabilities without adverse effects.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with COPD who have a stable clinical condition and meet specific pulmonary function criteria.
Not a fit: Patients with other pulmonary diseases, metabolic disorders, or recent respiratory infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the quality of life and physical function in COPD patients.
How similar studies have performed: Previous studies have shown positive outcomes with resistance training in COPD patients, suggesting that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * COPD clinical definition according to GOLD guidelines with forced expiratory volume (FEV1)/ forced vital capacity (FVC) \< 70%, and FEV1 \< 50% of predicted * stable clinical condition Exclusion Criteria: * pulmonary diseases other than COPD * type II diabetes or other metabolic diseases * malign disease * a respiratory tract infection within the last 4 wks * long oxygen therapy use.
Where this trial is running
Lumezzane, Brescia
- ICS Maugeri IRCCS, Respiratory Rehabilitation of the Institute of Lumezzane — Lumezzane, Brescia, Italy (Recruiting)
Study contacts
- Principal investigator: Mara Paneroni, MSc, PT — Istituti Clinici Scientifici Maugeri
- Study coordinator: Mara Paneroni, MSc, PT
- Email: mara.paneroni@icsmaugeri.it
- Phone: 0039+030+8253
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.